Exercise therapy for rheumatoid arthritis patients tapering molecular targeted therapies.

Not Applicable

Completed

• Conditions: rheumatoid arthritis

• Registration Number: JPRN-UMIN000049223
• Lead Sponsor: Osaka Metropolitan University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-10-17
• Study Completion: 2023-07-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up continuing
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Not provided

Exclusion Criteria

Patients who cannot stand or walk. Patients who are not allow to do exercise by the physician. Patients who have cognitive impairment. Patients for whom physicians judge as inappropriate to join this study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Disease activity of rheumatoid arthritis 16 weeks after the intervention.

Secondary Outcome Measures

Name	Time	Method
Maintenance rate of remission or low disease activity with tapered dose of molecular targeted therapies 16 weeks after the intervention. QOL of RA patients 16 weeks after the intervention.